Challenges of repurposing tetracyclines for the treatment of Alzheimer’s and Parkinson’s disease
The DOI matches its Crossref record; 261 of the 261 references it cites were found in a registry or an index.
Abstract
The novel antibiotic-exploiting strategy in the treatment of Alzheimer's (AD) and Parkinson's (PD) disease has emerged as a potential breakthrough in the field. The research in animal AD/PD models provided evidence on the antiamyloidogenic, anti-inflammatory, antioxidant and antiapoptotic activity of tetracyclines, associated with cognitive improvement. The neuroprotective effects of minocycline and doxycycline in animals initiated investigation of their clinical efficacy in AD and PD patients which led to inconclusive results and additionally to insufficient safety data on a long-standing doxycycline and minocycline therapy in these patient populations. The safety issues should be considered in two levels; in AD/PD patients (particularly antibiotic-induced alteration of gut microbiota and its consequences), and as a world-wide threat of development of bacterial resistance to these antibiotics posed by a fact that AD and PD are widespread incurable diseases which require daily administered long-lasting antibiotic therapy. Recently proposed subantimicrobial doxycycline doses should be thoroughly explored for their effectiveness and long-term safety especially in AD/PD populations. Keeping in mind the antibacterial activity-related far-reaching undesirable effects both for the patients and globally, further work on repurposing these drugs for a long-standing therapy of AD/PD should consider the chemically modified tetracycline compounds tailored to lack antimicrobial but retain (or introduce) other activities effective against the AD/PD pathology. This strategy might reduce the risk of long-term therapy-related adverse effects (particularly gut-related ones) and development of bacterial resistance toward the tetracycline antibiotic agents but the therapeutic potential and desirable safety profile of such compounds in AD/PD patients need to be confirmed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
In the citing paper
“Generally, although promising, two main concerns remain about the use of antibiotics in PD treatment: (i) antibiotics can kill some specific microbial populations leading to intestinal dysbiosis and neurological dysfunction and (ii) their prolonged and widespread intake would favor antibiotic resistance [213,300,301].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [301]
Citations
Cites
1 retracted
Kim, D. S., Ko, B., Ryuk, J. A., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082900 · Cited by 37
RetractedApoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853 · cited 1×
“There are two main apoptotic pathways (the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway) which converge on the execution pathway initiated by the cleavage of caspase-3 and subsequently resulting in the irreversible processes leading towards cell death (Elmore 2007).”
BackgroundCryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00018.2018 · Cited by 5,286
Oxidative stress, aging, and diseases
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s158513 · Cited by 3,979 · cited 1×
“2019) and epigenetic changes like methylation (Bradley-Whitman and Lovell 2013) but also because of the age-related decrease in brain insulin level and IR expression (Akintola and van Heemst 2015) and vulnerability to oxidative stress (Liguori et al. 2018).”
BackgroundGut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Oxidative Stress: A Key Modulator in Neurodegenerative Diseases
Singh, A., Kukreti, R., Saso, L., & Kukreti, S. (2019) · Molecules · doi:10.3390/molecules24081583 · Cited by 2,254 · cited 1×
“NO mediates lipid peroxidation and negatively affects complex I and IV of the mitochondrial electron transport chain in PD brain (Singh et al. 2019).”
BackgroundThe prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C., & Collin, F. (2018) · Redox Biology · doi:10.1016/j.redox.2017.10.014 · Cited by 2,185
The Emerging Evidence of the Parkinson Pandemic
Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R. (2018) · Journal of Parkinson’s Disease · doi:10.3233/jpd-181474 · Cited by 1,977
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750 · cited 2×
“2016; Tönnies and Trushina 2017) and PD (Picca et al.”
BackgroundNeuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“IL-1-positive activated microglia is co-localized with Aβ plaques and neurofibrillary tangles in AD while astrocytes express the receptors for binding inflammatory cytokines and chemokines, and additionally iNOS which contributes to NO-mediated toxicity (Calsolaro and Edison 2016).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Decreased mRNA/protein expression of IR, decreased IR-tyrosine kinase activity accompanied by decreased insulin receptor substrate-1 (IRS1), and PI3K/ Akt levels as well as increased serine (inhibitory) phosphorylation of IRS-1 and increased (harmful) GSK3 activity have been reported in the brain of AD patients post-m…”
BackgroundPathology of Neurodegenerative Diseases
Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665 · cited 2×
“2016; Dugger and Dickson 2017).”
BackgroundWu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 2×
“These findings are in contrast to minocycline ineffectiveness on astrocytes found in MPTP mouse model (Wu et al. 2002) which may indicate a difference in the targets between these two tetracycline drugs and/or additionally, the effects of these drugs in in vitro conditions may not be entirely identical to their effect…”
BackgroundResultBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172 · cited 1×
“Considering the neuroinflammation in PD, activated microglial cells and infiltrating T lymphocytes have been fund in the human substantia nigra (Brochard et al. 2009; McGeer et al. 1988).”
BackgroundMatthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3063 · Cited by 1,124 · cited 1×
“9 million people over the age of 65 (Matthews et al. 2019).”
BackgroundMetalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060 · cited 1×
“MMPs are zinc-dependent proteases involved in proteolysis of the extracellular matrix which contribute to the inflammation process and their upregulation can contribute to demyelinisation, neurotoxicity and neuroinflammation (Yong et al. 2001).”
BackgroundChen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K. B., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,051
Yrjänheikki, J., Tikka, T., Keinänen, R., Goldsteins, G., Chan, P. H., & Koistinaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,038 · cited 1×
“However, minocycline did not exert an inhibitory activity on astrogliosis as found in a model of focal brain ischemia (Yrjänheikki et al. 1999).”
BackgroundNau, R., Sörgel, F., & Eiffert, H. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00007-10 · Cited by 1,026
Role of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Mechanism of Oxidative Stress in Neurodegeneration
Gandhi, S., & Abramov, A. Y. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/428010 · Cited by 960 · cited 3×
“Oxidative stress and generation of ROS play a significant role also in PD pathophysiology; elevated levels of oxidized lipids, proteins, and DNA, along with reduced levels of glutathione are found in the substantia nigra of PD patients (Gandhi and Abramov 2012).”
BackgroundInfluentialTikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958 · cited 9×
“Increased levels of pro-inflammatory cytokines like TNF-α, IL-1β and IL-6, and decreased levels of neurotrophins such 1 3 as brain-derived neurotrophic factor (BDNF), have been found in the nigrostriatal region of postmortem PD patients (Nagatsu and Sawada 2005).”
BackgroundInfluentialMinocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Role of neuroinflammation in neurodegenerative diseases (Review)
CHEN, W.-W., ZHANG, X., & HUANG, W.-J. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.4948 · Cited by 932
Prusiner, S. B., Scott, M. R., DeArmond, S. J., & Cohen, F. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81163-0 · Cited by 923
Gut Microbiota is Altered in Patients with Alzheimer’s Disease
Zhuang, Z.-Q., Shen, L.-L., Li, W.-W., Fu, X., Zeng, F., Gui, L., Lü, Y., Cai, M., Zhu, C., Tan, Y.-L., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180176 · Cited by 885 · cited 1×
“The composition of the gut microbiota can be significantly affected by the therapy with orally administered antibiotic which has led to the conclusion that such an antibiotic agent can have both positive (protection against the harmful microorganisms in the condition of developed dysbiosis and thus a reduction of neur…”
ResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806 · cited 1×
“9 μg/ml (Agwuh and MacGowan 2006) and dose of 40 mg/day produces a plasma concentration around 0.”
BackgroundMicrobiota-Brain-Gut Axis and Neurodegenerative Diseases
Quigley, E. M. M. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0802-6 · Cited by 804
Impact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789 · cited 1×
“Given the role of NO in MPTP neurotoxicity, reduction of iNOS as well as of caspase 1 expression with minocycline has been demonstrated (Du et al. 2001).”
BackgroundOxidative stress in the aging substantia nigra and the etiology of Parkinson's disease
Trist, B. G., Hare, D. J., & Double, K. L. (2019) · Aging Cell · doi:10.1111/acel.13031 · Cited by 778 · cited 1×
“Due to that it is susceptible to damage caused by ROS and RNS particularly in ageing and age-related diseases like AD and PD ( Luo et al. 2020; Trist et al. 2019).”
BackgroundTetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768 · cited 1×
“They interfere with cytokine production from neutrophils and macrophages during inflammatory conditions, in particular suppression of TNF-α, IL-1β, and IL-6, found following the tetracyclines treatment of inflammatory skin disorders (Sapadin and Fleischmajer 2006).”
BackgroundBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
Tetracycline Antibiotics and Resistance
Grossman, T. H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025387 · Cited by 725 · cited 1×
“…is usually due to one or more of the following: the acquisition of mobile genetic elements carrying tetracycline-specific resistance genes, mutations within the ribosomal binding site, and/or chromosomal mutations leading to increased expression of intrinsic resistance mechanisms (Grossman 2016).”
BackgroundClinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · cited 1×
“Due to all mentioned above, a new trend of repurposing the drugs already approved in other indications for targeting the common pathophysiological mechanisms underlying AD and PD, has recently emerged in NDs research, putting into focus also the efficacy of several antibiotics as possible anti-AD/ PD agents (Yiannopou…”
BackgroundCurrent and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Non-motor symptoms in Parkinson's disease
Pfeiffer, R. F. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.004 · Cited by 644 · cited 1×
“As the second most common ND, idiopathic PD clinically presents primarily by motor dysfunction (tremor, rigidity, impaired balance, and loss of spontaneous movement) but also by a wide range of non-motor symptoms like dementia and changes in personality, sleep and mood (Pfeiffer 2016).”
BackgroundKim, M.-S., Kim, Y., Choi, H., Kim, W., Park, S., Lee, D., Kim, D. K., Kim, H. J., Choi, H., Hyun, D.-W., et al. (2020) · Gut · doi:10.1136/gutjnl-2018-317431 · Cited by 614
Ageing, age-related diseases and oxidative stress: What to do next?
Luo, J., Mills, K., le Cessie, S., Noordam, R., & van Heemst, D. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100982 · Cited by 581
Insulin in the brain: There and back again
Banks, W. A., Owen, J. B., & Erickson, M. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.006 · Cited by 574
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · cited 1×
“Deposition of Aβ plaques causes damage also to mitochondria with ROS production disrupting the electron transport chain (Swerdlow et al. 2010).”
BackgroundCraft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A., Sanchorawala, V., Schönland, S. O., Palladini, G., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 552
Energy metabolism and inflammation in brain aging and Alzheimer’s disease
Yin, F., Sancheti, H., Patil, I., & Cadenas, E. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.200 · Cited by 538 · cited 1×
“However, despite of the above mentioned possible triggers, it is still not fully understood whether neuroinflammation is a driven force of neurodegenerative disorders or is it a consequence of the metabolic dysfunction occurring earlier in the progression of diseases (Yin et al. 2016).”
BackgroundBacterial resistance to tetracycline: mechanisms, transfer, and clinical significance
Speer, B. S., Shoemaker, N. B., & Salyers, A. A. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.4.387 · Cited by 517 · cited 1×
“Conjugative plasmids have significantly contributed to the spread of efflux genes within the gram-negative and the gram-positive bacteria (Speer et al. 1992).”
BackgroundStress-induced Apoptosis Associated with Null Mutation of ADAR1 RNA Editing Deaminase Gene
Wang, Q., Miyakoda, M., Yang, W., Khillan, J., Stachura, D. L., Weiss, M. J., & Nishikura, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310162200 · Cited by 501 · cited 3×
“2000) but also inhibits pro-apoptotic Ca2+- and Bid-induced mitochondrial cytochrome c release and upregulates antiapoptotic factor Bcl-2 (Wang et al. 2004).”
BackgroundInfluentialKamat, P. K., Kalani, A., Rai, S., Swarnkar, S., Tota, S., Nath, C., & Tyagi, N. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9053-6 · Cited by 500
Gender and incidence of dementia in the Framingham Heart Study from mid‐adult life
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. A., Dufouil, C., & Seshadri, S. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.005 · Cited by 499
A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases
Amin, A. R., Attur, M. G., Thakker, G. D., Patel, P. D., Vyas, P. R., Patel, R. N., Patel, I. R., & Abramson, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14014 · Cited by 474
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Antibiotics, gut microbiota, and Alzheimer’s disease
Angelucci, F., Cechova, K., Amlerova, J., & Hort, J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1494-4 · Cited by 454
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453 · cited 5×
“The first such study was a randomized, double-blind, phase II futility clinical trial in 200 patients diagnosed of PD within 5 years who did not require drug therapy for the management of symptoms and were randomized (1:1:1) to receive creatine 10 g/day, minocycline 200 mg/day, or matching placebo for 12 months (NINDS…”
BackgroundMethodInfluentialMinocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447 · cited 2×
“Beside some review articles dealing with tetracyclines’ therapeutic potential in animal PD model (Kim and Suh 2009; Orsucci et al. 2009) the only one metaanalysis focused on this topic is the one mentioned previously for AD models which explored the effectiveness of minocycline (Li and Schluesener 2013).”
BackgroundEpidemiology of Parkinson's disease
Elbaz, A., Carcaillon, L., Kab, S., & Moisan, F. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2015.09.012 · Cited by 445
Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease
Sun, M.-F., & Shen, Y.-Q. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.004 · Cited by 445 · cited 2×
“2016; Sun and Shen 2018; Vendrik et al.”
ResultPicca, A., Calvani, R., Coelho-Junior, H. J., Landi, F., Bernabei, R., & Marzetti, E. (2020) · Antioxidants · doi:10.3390/antiox9080647 · Cited by 437
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434 · cited 1×
“2014; De La Monte and Tong 2014; Hoyer 2004) and PD (Athauda and Foltynie 2016; Yang et al.”
BackgroundTetracyclines, molecular and clinical aspects
Chopra, I., Hawkey, P. M., & Hinton, M. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.3.245 · Cited by 421
Griffin, M. O., Fricovsky, E., Ceballos, G., & Villarreal, F. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00047.2010 · Cited by 413
Fecal Microbiota Transplantation in Neurological Disorders
Vendrik, K. E. W., Ooijevaar, R. E., de Jong, P. R. C., Laman, J. D., van Oosten, B. W., van Hilten, J. J., Ducarmon, Q. R., Keller, J. J., Kuijper, E. J., & Contarino, M. F. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00098 · Cited by 413 · cited 1×
“In line with that, it has been suggested that gut microbial dysbiosis may lead to alterations in brain functions including the memory impairment, anxiety, and other cognitive dysfunctions and was further supported by the findings of gastrointestinal symptoms and reduced gut microbial diversity in AD and PD patients wi…”
ResultInflammatory Process in Parkinsons Disease: Role for Cytokines
Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412 · cited 1×
“Increased levels of pro-inflammatory cytokines like TNF-α, IL-1β and IL-6, and decreased levels of neurotrophins such 1 3 as brain-derived neurotrophic factor (BDNF), have been found in the nigrostriatal region of postmortem PD patients (Nagatsu and Sawada 2005).”
BackgroundPrevalencia e incidencia de la enfermedad de Alzheimer en Europa: metaanálisis
Niu, H., Álvarez-Álvarez, I., Guillén-Grima, F., & Aguinaga-Ontoso, I. (2017) · Neurología · doi:10.1016/j.nrl.2016.02.016 · Cited by 412
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
Kriz, J., Nguyen, M. D., & Julien, J.-P. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0487 · Cited by 411 · cited 1×
“Experiments in mice expressing a mutant superoxide dismutase (SOD1G37R) and mimicking human ALS, demonstrated that daily administration of minocycline (1 g/kg) into the diet, initiated at late presymptomatic stage (7 or 9 months of age), delayed the onset of motor neuron degeneration, muscle strength decline, and incr…”
BackgroundButterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403 · cited 2×
“However, pathological Aβ1-40 and Aβ1-42 fragments which dominate in AD condition demonstrate pro-oxidative activity confirmed by detection of increased markers of protein oxidation and lipid peroxidation in primary neuronal culture, cortical synaptosomes and astrocytes (Butterfield and Boyd-Kimball 2018).”
BackgroundAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383 · cited 2×
“2014; De La Monte and Tong 2014; Hoyer 2004) and PD (Athauda and Foltynie 2016; Yang et al.”
BackgroundThaker, M., Spanogiannopoulos, P., & Wright, G. D. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0172-6 · Cited by 378 · cited 2×
“Even if older tetracyclines become obsolete as clinically useful antibiotics, tetracycline resistance transfer elements will continue to be a cause for concern because they can carry other resistance genes and confer resistance to other antibiotics (Thaker et al. 2010).”
BackgroundThe Role of NADPH Oxidases and Oxidative Stress in Neurodegenerative Disorders
Tarafdar, A., & Pula, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123824 · Cited by 373 · cited 2×
“The nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) enzymes are involved in transfer of electrons across the plasma membrane to molecular oxygen, and generation of the superoxide anion and subsequently ROS, H2O2 and hydroxyl radicals (Tarafdar and Pula 2018).”
BackgroundInflammasomes in neuroinflammation and changes in brain function: a focused review
Singhal, G., Jaehne, E. J., Corrigan, F., Toben, C., & Baune, B. T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00315 · Cited by 365 · cited 1×
“Pro-inflammatory cytokines associated with promotion and deterioration of NDs are interleukin (IL)1β, IL-6, interferon-gamma (IF-γ) and macrophage migration inhibitory factor (Singhal et al. 2014).”
BackgroundFamilial and sporadic fatal insomnia
Montagna, P., Gambetti, P., Cortelli, P., & Lugaresi, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00323-5 · Cited by 354
He, Y., Appel, S., & Le, W. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02681-6 · Cited by 348
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Oxidative toxicity in diabetes and Alzheimer’s disease: mechanisms behind ROS/ RNS generation
Ahmad, W., Ijaz, B., Shabbiri, K., Ahmed, F., & Rehman, S. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0379-z · Cited by 330 · cited 1×
“Numerous studies have pointed to the increased markers of oxidation in brain of AD patients (Ahmad et al. 2017; Galasko and Montine 2010; Mantzavinos and Alexiou 2017; Skoumalová and Hort 2012; Wojsiat et al. 2017).”
BackgroundKraus, R. L., Pasieczny, R., Lariosa‐Willingham, K., Turner, M. S., Jiang, A., & Trauger, J. W. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03219.x · Cited by 321 · cited 2×
“Direct scavenging of ROS, superoxide and peroxynitrite as well as H2O2 quenching by minocycline has been shown in several cell-free mixed-radical assays (Kraus et al. 2005).”
BackgroundMechanisms of inflammatory neurodegeneration: iNOS and NADPH oxidase
Brown, G. C. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351119 · Cited by 316 · cited 3×
“Due to that it is susceptible to damage caused by ROS and RNS particularly in ageing and age-related diseases like AD and PD ( Luo et al.”
BackgroundInfluentialNeuroinflammation in the normal aging hippocampus
Barrientos, R. M., Kitt, M. M., Watkins, L. R., & Maier, S. F. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.007 · Cited by 315
Oxidative Stress in Alzheimer’s Disease: Why Did Antioxidant Therapy Fail?
Persson, T., Popescu, B. O., & Cedazo-Minguez, A. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/427318 · Cited by 312
Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Cai, H., Cong, W.-N., Ji, S., Rothman, S., Maudsley, S., & Martin, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015064 · Cited by 306 · cited 1×
“Because of the complexity of these insulin-regulated processes involved in important brain functions, it is to be expected that impaired insulin function and IRBS development is strongly associated with neurodegenerative diseases (Cai et al. 2012; Craft and Watson 2004; De La Monte 2017).”
BackgroundThe Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Roberts, M. C. (2003) · Clinical Infectious Diseases · doi:10.1086/367622 · Cited by 296 · cited 1×
“…often due to the acquisition of new genes, which code for energydependent efflux of tetracyclines or for a cytoplasmic protein that interacts with the ribosomes and allows the ribosomes to proceed with protein synthesis even in the presence of high intracellular levels of the drug (Roberts 2003).”
BackgroundBiomarkers for Alzheimer's Disease Diagnosis
Mantzavinos, V., & Alexiou, A. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170203125942 · Cited by 295 · cited 2×
“2017; Galasko and Montine 2010; Mantzavinos and Alexiou 2017; Skoumalová and Hort 2012; Wojsiat et al.”
Choi, Y., Kim, H.-S., Shin, K. Y., Kim, E.-M., Kim, M., Kim, H.-S., Park, C. H., Jeong, Y. H., Yoo, J., Lee, J.-P., et al. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301377 · Cited by 289
Insulin Resistance and Oxidative Stress in the Brain: What’s New?
Maciejczyk, M., Żebrowska, E., & Chabowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040874 · Cited by 262 · cited 1×
“Therefore, a lot of pathological abnormalities in AD might be a consequence of IRBS, but it has to be mentioned that their interaction seems to be a bidirectional one since Aβ itself is capable of impairing the insulin transmission in AD brain at different levels (de la Monte 2017) as well as that IRBS and impaired gl…”
BackgroundAnti‐amyloidogenic activity of tetracyclines: studies in vitro
Forloni, G., Colombo, L., Girola, L., Tagliavini, F., & Salmona, M. (2001) · FEBS Letters · doi:10.1016/s0014-5793(00)02380-2 · Cited by 242 · cited 1×
“1 3 both the formation of amyloid fibrils and the resistance of Aβ1–42 fibrils to trypsin digestion, demonstrating also a de-fibrillogenic effect against pre-formed Aβ1–42 fibrils (Forloni et al. 2001).”
BackgroundMolecular pathology of neurodegenerative diseases: principles and practice
Kovacs, G. G. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-205952 · Cited by 242
A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease
Loeb, M. B., Molloy, D. W., Smieja, M., Standish, T., Goldsmith, C. H., Mahony, J., Smith, S., Borrie, M., Decoteau, E., Davidson, W., et al. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52109.x · Cited by 241
Heterogeneity in male to female risk for Parkinson's disease
Taylor, K. S. M., Cook, J. A., & Counsell, C. E. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.104695 · Cited by 238
Tran, T. T. T., Corsini, S., Kellingray, L., Hegarty, C., Le Gall, G., Narbad, A., Müller, M., Tejera, N., O'Toole, P. W., Minihane, A.-M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900071r · Cited by 233 · cited 1×
“The composition of the gut microbiota can be significantly affected by the therapy with orally administered antibiotic which has led to the conclusion that such an antibiotic agent can have both positive (protection against the harmful microorganisms in the condition of developed dysbiosis and thus a reduction of neur…”
ResultNeuroprotective and Anti–Human Immunodeficiency Virus Activity of Minocycline
Zink, M. C. (2005) · JAMA · doi:10.1001/jama.293.16.2003 · Cited by 231 · cited 1×
“Minocycline treatment was reported to reduce the incidence and severity of encephalitis in simian immunodeficiency virus macaque model of HIV-associated neurological disease by decreasing cytotoxic lymphocyte infiltration into the brain, and it reduced p38 activation in primary lymphocytes in vitro (Zink et al. 2011).”
BackgroundEvaluation of Models of Parkinson's Disease
Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00503 · Cited by 226
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J. R., Childs, M., Walton, S., Harman, K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30560-3 · Cited by 226
The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia
Yang, L., Wang, H., Liu, L., & Xie, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00073 · Cited by 226 · cited 1×
“2014; De La Monte and Tong 2014; Hoyer 2004) and PD (Athauda and Foltynie 2016; Yang et al. 2018), possibly as a common shared pathophysiology (Barilar et al.”
BackgroundControl of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Yoon, K. W., Byun, S., Kwon, E., Hwang, S.-Y., Chu, K., Hiraki, M., Jo, S.-H., Weins, A., Hakroush, S., Cebulla, A., et al. (2015) · Science · doi:10.1126/science.1261669 · Cited by 224 · cited 1×
“Recent data indicate that doxycycline exhibits antiapoptotic effects at low concentrations in HeLa cells by inhibition of FasL-induced extrinsic pathway and consequent inhibition of caspase activation which has not been achieved by minocycline and tetracycline at same concentrations (Yoon et al. 2015).”
BackgroundMinocycline affects microglia activation, Aβ deposition, and behavior in APP‐tg mice
Seabrook, T. J., Jiang, L., Maier, M., & Lemere, C. A. (2006) · Glia · doi:10.1002/glia.20338 · Cited by 223 · cited 2×
“It is important to emphasize that AD models were explored in only 5/19 studies, among which 3/5 used transgenic mice implying the familial form of AD (Fan et al. 2007; Ferretti et al. 2012; Seabrook et al. 2006), while 1/5 study used non-transgenic rats treated intracerebroventricularly with an immunotoxin p75-saporin…”
BackgroundAbramov, A. Y., Canevari, L., & Duchen, M. R. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.006 · Cited by 223 · cited 1×
“1 3 accumulation activates NADPH oxidase in astrocyte cells, but with different mechanism than in microglia, referring to induction of calcium entry into them (Abramov et al. 2004).”
BackgroundPharmacokinetic studies on minocycline in man
Macdonald, H., Kelly, R. G., Allen, E. S., Noble, J. F., & Kanegis, L. A. (1973) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1973145852 · Cited by 222 · cited 1×
“However, due to more favorable safety profile in CNS side effects, doxycycline seems to remain the preferred oral antibiotic for treatment of the indicated CNS infections, for instance Lyme neuroborreliosis (Dotevall and Hagberg 1999; Macdonald et al. 1973).”
BackgroundBiomarkers of Oxidative Damage and Inflammation in Alzheimer's Disease
Galasko, D., & Montine, T. J. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.89 · Cited by 221 · cited 1×
“2017; Galasko and Montine 2010; Mantzavinos and Alexiou 2017; Skoumalová and Hort 2012; Wojsiat et al.”
BackgroundMerlini, G., Ascari, E., Amboldi, N., Bellotti, V, Arbustini, E., Perfetti, V, Ferrari, M., Zorzoli, I., Marinone, M. G., & Garini, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2959 · Cited by 205
Haïk, S., Marcon, G., Mallet, A., Tettamanti, M., Welaratne, A., Giaccone, G., Azimi, S., Pietrini, V., Fabreguettes, J.-R., Imperiale, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70307-7 · Cited by 203
Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations
Pierantozzi, M., Pietroiusti, A., Brusa, L., Galati, S., Stefani, A., Lunardi, G., Fedele, E., Sancesario, G., Bernardi, G., Bergamaschi, A., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000221672.01272.ba · Cited by 199
Fan, R., Xu, F., Previti, M. L., Davis, J., Grande, A. M., Robinson, J. K., & Van Nostrand, W. E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4371-06.2007 · Cited by 196 · cited 11×
“Considering the anti-Aβ activity of tetracycline drugs, Forloni and coworkers were among the first who reported that 5-day co-incubation of synthetic Aβ1–42 with tetracycline or doxycycline (10 µM–1 mM) significantly decreased 1 3 both the formation of amyloid fibrils and the resistance of Aβ1–42 fibrils to trypsin di…”
BackgroundInfluentialMinocycline for Short‐Term Neuroprotection
Elewa, H. F., Hilali, H., Hess, D. C., Machado, L. S., & Fagan, S. C. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.4.515 · Cited by 196 · cited 1×
“Minocycline demonstrated anti-inflammatory and antiapoptotic effects on neurons and microglial cells in several models of brain injury like global and focal cerebral ischemia, traumatic brain injury, spinal cord injury and intracerebral hemorrhage, in which it provided both reduction in tissue injury and improvement i…”
Background16S rRNA Mutation Associated with Tetracycline Resistance in a Gram-Positive Bacterium
Ross, J. I., Eady, E. A., Cove, J. H., & Cunliffe, W. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1702 · Cited by 194
Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3762 · Cited by 194
Epigenetic changes in the progression of Alzheimer's disease
Bradley-Whitman, M. A., & Lovell, M. A. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.005 · Cited by 193 · cited 2×
“2019) and epigenetic changes like methylation (Bradley-Whitman and Lovell 2013) but also because of the age-related decrease in brain insulin level and IR expression (Akintola and van Heemst 2015) and vulnerability to oxidative stress (Liguori et al.”
BackgroundGasparrini, A. J., Markley, J. L., Kumar, H., Wang, B., Fang, L., Irum, S., Symister, C. T., Wallace, M., Burnham, C.-A. D., Andleeb, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0966-5 · Cited by 191
Giovannini, M. G., Scali, C., Prosperi, C., Bellucci, A., Vannucchi, M. G., Rosi, S., Pepeu, G., & Casamenti, F. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0538 · Cited by 190
Deleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease
Hirsch, E. C., & Standaert, D. G. (2021) · Movement Disorders · doi:10.1002/mds.28075 · Cited by 189
Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N., Trenkwalder, C., Sixel‐Döring, F., Herting, B., Kamm, C., et al. (2010) · Movement Disorders · doi:10.1002/mds.22732 · Cited by 187
Nitric Oxide and Reactive Oxygen Species in Parkinson's Disease
Tieu, K., Ischiropoulos, H., & Przedborski, S. (2003) · IUBMB Life · doi:10.1080/1521654032000114320 · Cited by 180
Fatty acids and oxidative stress in psychiatric disorders
Tsaluchidu, S., Cocchi, M., Tonello, L., & Puri, B. K. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-s1-s5 · Cited by 179 · cited 1×
“Double bonding allows the removal of hydrogen ions and enhanced lipid peroxidation, the prominent features of degenerative alterations occurring in brain (Tsaluchidu et al. 2008).”
BackgroundMargolis, D. J., Fanelli, M., Hoffstad, O., & Lewis, J. D. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.303 · Cited by 177
Nikodemova, M., Duncan, I. D., & Watters, J. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03520.x · Cited by 176
Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters
Tagliavini, F., McArthur, R. A., Canciani, B., Giaccone, G., Porro, M., Bugiani, M., Lievens, P. M.-J., Bugiani, O., Peri, E., Dall’Ara, P., et al. (1997) · Science · doi:10.1126/science.276.5315.1119 · Cited by 176 · cited 1×
“1 3 have been chosen particularly due to the structural analogies of tetracycline with Congo red (an azo dye used for specific detection of pathological Aβ aggregation seen as apple-green birefringence under polarized light) (Ladewig 1945), and iododoxorubicin (an anthracycline anti-cancer drug which inhibits the form…”
BackgroundA Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results
(2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181342f32 · Cited by 174
Genomic integrity and the ageing brain
Chow, H.-M., & Herrup, K. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4020 · Cited by 174 · cited 2×
“One should not forget that aging itself is associated with increased tendency to development of chronic diseases and is considered to be a major risk factor for NDs due to the age-related degenerative changes and genomic instability (Chow and Herrup 2015; Hou et al.”
BackgroundTagliavini, F., Forloni, G., Colombo, L., Rossi, G., Girola, L., Canciani, B., Angeretti, N., Giampaolo, L., Peressini, E., Awan, T., et al. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3840 · Cited by 173 · cited 4×
“Tetracycline structure, in particular the nature and position of polar substituents, seems to play an important role in the interaction with hydrophobic domains of PrP peptides interfering with the conversion process and/or PrPSc assembly (Tagliavini et al. 2000).”
BackgroundInfluentialMinocycline and doxycycline are not beneficial in a model of Huntington's disease
Smith, D. L., Woodman, B., Mahal, A., Sathasivam, K., Ghazi‐Noori, S., Lowden, P. A. S., Bates, G. P., & Hockly, E. (2003) · Annals of Neurology · doi:10.1002/ana.10614 · Cited by 173 · cited 2×
“The group of Smith and coworkers performed a set of experiments to test the ability of tetracycline, doxycycline, and minocycline to reduce aggregation of huntingtin in vitro as well as to explore the therapeutic potential of these tetracyclines in modifying the disease in its animal model in vivo (Smith et al. 2003).”
BackgroundThe Amyloid Phenomenon and Its Significance in Biology and Medicine
Dobson, C. M., Knowles, T. P. J., & Vendruscolo, M. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033878 · Cited by 173
Antibiotics: Pharmacokinetics, toxicity, resistance and multidrug efflux pumps
Yılmaz, Ç., & Özcengiz, G. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.005 · Cited by 172 · cited 1×
“All of these mechanisms reduce the efficacy of tetracyclines, calling for increased rigour when clinicians prescribe these drugs (Ian and Marilyn 2001; Yılmaz and Özcengiz 2017).”
BackgroundRapamycin and Alzheimer’s disease: Time for a clinical trial?
Kaeberlein, M., & Galvan, V. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar4289 · Cited by 171
Doxycycline Suppresses Microglial Activation by Inhibiting the P38 MAPK and NF-KB Signaling Pathways
Santa-Cecília, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Acuña, L., Silva, R. L., Michel, P. P., Del-Bel, E., Cunha, T. M., & Raisman-Vozari, R. (2016) · Neurotoxicity Research · doi:10.1007/s12640-015-9592-2 · Cited by 165
Biscaro, B., Lindvall, O., Tesco, G., Ekdahl, C. T., & Nitsch, R. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000330363 · Cited by 164
pH-Partition Behavior of Tetracyclines
Colaizzi, J. L., & Klink, P. R. (1969) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600581003 · Cited by 164 · cited 1×
“…and minocycline reveals that minocycline has the highest lipophilicity among these three tetracycline drugs (0.025, 0.600 and 1.100, respectively) which contributes to the fact that minocycline crosses the BBB much more readily than doxycycline (or tetracycline) (Colaizzi and Klink 1969).”
BackgroundInfluentialHoyer, S. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200082 · Cited by 161 · cited 1×
“Binding of insulin to IR triggers its tyrosine kinase activity and the downstream signaling cascade which involves two main signaling pathways; phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) pathway, respectively (Hoyer 2002).”
BackgroundMoroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P. L., McGeer, E. G., & Hirayama, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00313602 · Cited by 159
Minocycline Enhances MPTP Toxicity to Dopaminergic Neurons
Yang, L., Sugama, S., Chirichigno, J. W., Gregorio, J., Lorenzl, S., Shin, D. H., Browne, S. E., Shimizu, Y., Joh, T. H., Beal, M. F., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10709 · Cited by 158
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
Ward, J. E., Ren, R., Toraldo, G., Soohoo, P., Guan, J., O’Hara, C., Jasuja, R., Trinkaus‐Randall, V., Liao, R., Connors, L. H., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351643 · Cited by 153 · cited 1×
“The successfulness of antiprion activity of tetracycline initiated further research on tetracyclines activity against other amyloidogenic proteins like transthyretin, β2-microglubulin amyloid fibrils and immunoglobulin lightchain, and, most importantly, against Aβ and α-synuclein as the AD and PD neuropathological hal…”
BackgroundTetracyclines: Drugs with Huge Therapeutic Potential
Bahrami, F., L. Morris, D., & H. Pourgholami, M. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712798868977 · Cited by 150
Gut microbiota modulates drug pharmacokinetics
Zhang, J., Zhang, J., & Wang, R. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1497647 · Cited by 150 · cited 1×
“1 3 a number of metabolic activities, and can modulate the pharmacokinetics (absorption and/or metabolism) of the various drugs, and by that also their therapeutic outcome as extensively reviewed by Zhang and coworkers (Zhang et al. 2018).”
BackgroundHelicobacter pylori infection is associated with worse severity of Parkinson's disease
Tan, A. H., Mahadeva, S., Marras, C., Thalha, A. M., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Loke, M. F., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.12.009 · Cited by 148 · cited 1×
“, eradication of Helicobacter pylori, a microorganism whose prevalence has been found increased in PD patients) (Tan et al. 2015).”
BackgroundZilka, N., Kazmerova, Z., Jadhav, S., Neradil, P., Madari, A., Obetkova, D., Bugos, O., & Novak, M. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-47 · Cited by 147 · cited 1×
“Due to ageing, its function shows signs of impairment and chronic inflammation, leading to induction of neurodegeneration (Zilka et al. 2012).”
BackgroundProtein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms
Forloni, G., Terreni, L., Bertani, I., Fogliarino, S., Invernizzi, R. W., Assini, A., Ribizzi, G., Negro, A., Calabrese, E., Volonté, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00076-3 · Cited by 147 · cited 1×
“) in old double (APP/PS1) transgenic AD resulted in cognitive improvement but was not associated with plaque load reduction under the achieved brain concentration lower than 1 μM that were previously shown to be below the concentration threshold for antiaggregating effects observed in vitro (Balducci et al. 2018; Forl…”
BackgroundAnimal models of Parkinson's disease: An updated overview
Gubellini, P., & Kachidian, P. (2015) · Revue Neurologique · doi:10.1016/j.neurol.2015.07.011 · Cited by 146 · cited 1×
“…dopaminergic transporter (DAT) and induces oxidative stress-related cytotoxicity and mitochondrial fragmentation, or by rotenone, a naturally occurring organic pesticide that induces mitochondrial dysfunction and ultimately cell loss in the nigrostriatal pathway (Gubellini and Kachidian 2015).”
BackgroundClassification Framework and Chemical Biology of Tetracycline-Structure-Based Drugs
Fuoco, D. (2012) · Antibiotics · doi:10.3390/antibiotics1010001 · Cited by 138 · cited 1×
“Among the existing groups/generations of tetracyclines (the tetracycline natural product, tetracycline semi-synthetic derivatives and chemically modified tetracyclines), the most clinically used as antibiotic drugs are semisynthetic compounds doxycycline and minocycline (Fuoco 2012).”
BackgroundInsulin receptor mRNA in the substantia nigra in Parkinson's disease
Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimurâ, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 137 · cited 1×
“Decreased expression of insulin and IR as well as increased expression of markers of IRBS have been found also in the brain of PD patients (Moroo et al. 1994; Takahashi et al. 1996; Tong et al. 2009), and like for AD, literature data suggest that the interaction is bidirectional, and that also misfolded α-synuclein mi…”
BackgroundAnti‐Inflammatory Properties of Low and High Doxycycline Doses: An In Vitro Study
Di Caprio, R., Lembo, S., Di Costanzo, L., Balato, A., & Monfrecola, G. (2015) · Mediators of Inflammation · doi:10.1155/2015/329418 · Cited by 136
Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review
Avgerinos, K. I., Kalaitzidis, G., Malli, A., Kalaitzoglou, D., Myserlis, P. G., & Lioutas, V.-A. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8768-0 · Cited by 136 · cited 1×
“1998) while intranasal insulin administration leads to improvement in cognitive functions in certain population of AD patients (Avgerinos et al. 2018).”
BackgroundYim, C. W., Flynn, N. M., & Fitzgerald, F. T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.2.347 · Cited by 133 · cited 2×
“Additionally, when interpreting the in vitro results, it is important to keep in mind the ratio between the particular tetracycline drug and the aggregating protein concentration as most of the studies were performed with this molar ratio being 1:1 while doxycycline achieves brain concentration in the order of μg/mL a…”
BackgroundCardoso, I., Merlini, G., & Saraiva, M. J. (2003) · The FASEB Journal · doi:10.1096/fj.02-0764com · Cited by 131 · cited 1×
“The successfulness of antiprion activity of tetracycline initiated further research on tetracyclines activity against other amyloidogenic proteins like transthyretin, β2-microglubulin amyloid fibrils and immunoglobulin lightchain, and, most importantly, against Aβ and α-synuclein as the AD and PD neuropathological hal…”
BackgroundMinocycline reduces the development of abnormal tau species in models of Alzheimer's disease
Noble, W., Garwood, C., Stephenson, J., Kinsey, A. M., Hanger, D. P., & Anderton, B. H. (2009) · The FASEB Journal · doi:10.1096/fj.08-113795 · Cited by 130
Molloy, D. W., Standish, T. I., Zhou, Q., Guyatt, G., & The DARAD Study Group (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3846 · Cited by 128
Insulin, Aging, and the Brain: Mechanisms and Implications
Akintola, A. A., & van Heemst, D. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00013 · Cited by 124
Effect of Antibiotics on the Oropharyngeal Flora in Patients With Acne
Levy, R. M., Huang, E. Y., Roling, D., Leyden, J. J., & Margolis, D. J. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.4.467 · Cited by 120 · cited 1×
“A study has demonstrated that nearly 35% of the patients with acne who were receiving antibiotic therapy and who had no URTI (upper respiratory tract infection) symptoms had group A streptococci in their upper airway and that nearly 85% of these strains were resistant to tetracyclines (Levy et al. 2003).”
BackgroundAntibiotic Treatment of Acne May Be Associated With Upper Respiratory Tract Infections
Margolis, D. J., Bowe, W. P., Hoffstad, O., & Berlin, J. A. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.9.1132 · Cited by 120
Amin, A. R., Patel, R. N., Thakker, G. D., Lowenstein, C. J., Attur, M. G., & Abramson, S. B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00605-4 · Cited by 119
Schlienger, R. G., Bircher, A. J., & Meier, C. R. (2000) · Dermatology · doi:10.1159/000018387 · Cited by 119
González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., et al. (2017) · Scientific Reports · doi:10.1038/srep41755 · Cited by 119
Hegelmaier, T., Lebbing, M., Duscha, A., Tomaske, L., Tönges, L., Holm, J. B., Bjørn Nielsen, H., Gatermann, S. G., Przuntek, H., & Haghikia, A. (2020) · Cells · doi:10.3390/cells9020376 · Cited by 118
Doxycycline restrains glia and confers neuroprotection in a 6‐OHDA Parkinson model
Lazzarini, M., Martin, S., Mitkovski, M., Vozari, R. R., Stühmer, W., & Bel, E. D. (2013) · Glia · doi:10.1002/glia.22496 · Cited by 117 · cited 1×
“Oral (chow) treatment of 6-OHDA-induced mouse PD model with doxycycline in a dose of 40 mg/kg for 30 days decreased both astrocyte and microglia response to 6-OHDA in the globus pallidus and substantia nigra pars compacta as well the astrocyte reaction in the striatum (Lazzarini et al. 2013).”
BackgroundMinocycline and Lupuslike Syndrome in Acne Patients
Sturkenboom, M. C. J. M., Meier, C. R., Jick, H., & Stricker, B. H. C. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.5.493 · Cited by 117 · cited 1×
“Drug-induced lupus among those with acne is more common among users of minocycline and in young females (Schoonen et al. 2010; Sturkenboom et al. 1999).”
BackgroundExploring the Association Between Rosacea and Parkinson Disease: A Danish Nationwide Cohort Study
Egeberg, A., Hansen, P. R., Gislason, G. H., & Thyssen, J. P. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0022 · Cited by 116
Ferretti, M. T., Allard, S., Partridge, V., Ducatenzeiler, A., & Cuello, A. C. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-62 · Cited by 114 · cited 2×
“It is important to emphasize that AD models were explored in only 5/19 studies, among which 3/5 used transgenic mice implying the familial form of AD (Fan et al. 2007; Ferretti et al. 2012; Seabrook et al. 2006), while 1/5 study used non-transgenic rats treated intracerebroventricularly with an immunotoxin p75-saporin…”
BackgroundMartínez, E. M. G., Sanz‐Blasco, S., Karachitos, A., Bández, M. J., Fernández-Gómez, F.-J., Perez‐Alvarez, S., de Mera, R. M. M.-F., Jordán, M. J., Aguirre, N., Galindo, M. F., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.07.028 · Cited by 113
Resistance surveillance program report for selected European nations (2011)
Jones, R. N., Flonta, M., Gurler, N., Cepparulo, M., Mendes, R. E., & Castanheira, M. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2013.10.008 · Cited by 113
Keller, A. F., Gravel, M., & Križ, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.12.010 · Cited by 112
Successful Oral Doxycycline Treatment of Lyme Disease‐Associated Facial Palsy and Meningitis
Dotevall, L., & Hagberg, L. (1999) · Clinical Infectious Diseases · doi:10.1086/515145 · Cited by 110 · cited 2×
“However, due to more favorable safety profile in CNS side effects, doxycycline seems to remain the preferred oral antibiotic for treatment of the indicated CNS infections, for instance Lyme neuroborreliosis (Dotevall and Hagberg 1999; Macdonald et al.”
BackgroundTetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
Bortolanza, M., Nascimento, G. C., Socías, S. B., Ploper, D., Chehín, R. N., Raisman‐Vozari, R., & Bel, E. A. D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1913-1 · Cited by 109
Neuroprotection in Huntington??s disease: a 2-year study on minocycline
Bonelli, R. M., H??dl, A. K., Hofmann, P., & Kapfhammer, H.-P. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200411000-00004 · Cited by 108
Update on the use of memantine in Alzheimer’s disease
Marum, R. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4048 · Cited by 106 · cited 1×
“The lack of drugs for the symptomatic therapy is particularly problematic in the treatment of AD for which only four drugs are currently available on the market: donepezil, rivastigmine, galantamine and memantine (Van Marum 2009).”
BackgroundAnti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
Doxycycline in early CJD: a double-blinded randomised phase II and observational study
Varges, D., Manthey, H. G., Heinemann, U., Ponto, C., Schmitz, M., Schulz‐Schaeffer, W., Krasnianski, A., Breithaupt, M., Fincke, F., Kramer, K., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313541 · Cited by 106 · cited 3×
“In parallel, the same group of researchers conducted an observational study on CJD patients who received a compassionate treatment with doxycycline (100 mg/day, N = 55) or placebo (N = 33), so the results of both studies were also combined by means of a random-effects meta-analysis (Varges et al. 2017).”
BackgroundInfluentialGiorgetti, S., Raimondi, S., Pagano, K., Relini, A., Bucciantini, M., Corazza, A., Fogolari, F., Codutti, L., Salmona, M., Mangione, P., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178376 · Cited by 104
RAGE Expression and ROS Generation in Neurons: Differentiation versus Damage
Piras, S., Furfaro, A. L., Domenicotti, C., Traverso, N., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9348651 · Cited by 103 · cited 1×
“Accumulated Aβ facilitates the expression of the receptor for advanced glycation end products (RAGE) in microvascular endothelial cells neurons and microglia, which induces ROS mainly through the activity of NADPH oxidases (Piras et al. 2016).”
BackgroundGarcez, M. L., Mina, F., Bellettini-Santos, T., Carneiro, F. G., Luz, A. P., Schiavo, G. L., Andrighetti, M. S., Scheid, M. G., Bolfe, R. P., & Budni, J. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.010 · Cited by 102 · cited 1×
“In a non-transgenic mice AD model induced by intracerebroventricular administration of Aß1–42, high dose of minocycline (50 mg/kg/day per os) administered for 15–17 days improved the spatial memory (Garcez et al. 2017) and prevented the development of depression-like behavior (Amani et al.”
BackgroundParachikova, A., Vasilevko, V., Cribbs, D. H., LaFerla, F. M., & Green, K. N. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100204 · Cited by 100 · cited 1×
“Tetracyclines are generally safe but adverse effects can occur (Perdue and Standiford 1999).”
BackgroundDotevall, L., & Hagberg, L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.7.1078 · Cited by 98 · cited 1×
“…of CNS infection caused by susceptible microorganisms refers to doxycycline which, because of its good lipid solubility and passing of the blood–brain barrier (BBB), has been considered as a preferential choice of tetracycline drugs in such indications (Dotevall and Hagberg 1989; Karlsson et al.”
BackgroundA futility study of minocycline in Huntington's disease
Cudkowicz, M., & The Huntington Study Group DOMINO Investigators (2010) · Movement Disorders · doi:10.1002/mds.23236 · Cited by 97
Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine
Gu, Y., Walker, C., RYAN, M. E., Payne, J. B., & Golub, L. M. (2012) · Journal of Oral Microbiology · doi:10.3402/jom.v4i0.19227 · Cited by 96
Double-Refringence of the Amyloid-Congo-Red-Complex in Histological Sections
Ladewig, P. P. (1945) · Nature · doi:10.1038/156081a0 · Cited by 96 · cited 2×
“…with Congo red (an azo dye used for specific detection of pathological Aβ aggregation seen as apple-green birefringence under polarized light) (Ladewig 1945), and iododoxorubicin (an anthracycline anti-cancer drug which inhibits the formation of amyloid aggregates in vitro and in vivo)…”
BackgroundOral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review
Bienenfeld, A., Nagler, A. R., & Orlow, S. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0267-z · Cited by 94
A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses
Stoilova, T., Colombo, L., Forloni, G., Tagliavini, F., & Salmona, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400161p · Cited by 93 · cited 10×
“The chemical structure reveals linearly fused tetracyclic nucleus composed of A, B, C and D rings to which different functional groups and chains are attached in the upper and lower peripheral zones (Bortolanza et al. 2018; Stoilova et al. 2013) (Fig.”
BackgroundInfluentialThe Therapeutic Role of Minocycline in Parkinson’s Disease
Cankaya, S., Cankaya, B., Kilic, U., Kilic, E., & Yulug, B. (2019) · Drugs in Context · doi:10.7573/dic.212553 · Cited by 93 · cited 1×
“Beneficial effects of minocycline treatment manifested as block of the microglial activation have been reported as well in non-transgenic PD models (Cankaya et al. 2019).”
BackgroundMultiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century
Młynarczyk-Bonikowska, B., Majewska, A., Malejczyk, M., Młynarczyk, G., & Majewski, S. T. (2019) · Medical Microbiology and Immunology · doi:10.1007/s00430-019-00651-4 · Cited by 92
A Review: Treatment of Alzheimer’s Disease Discovered in Repurposed Agents
Appleby, B. S., Nacopoulos, D., Milano, N., Zhong, K., & Cummings, J. L. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000345791 · Cited by 90 · cited 1×
“Consistent with the recent findings that some antibiotic drugs demonstrate additionally one or more of these desirable activities (Appleby et al. 2013; Garrido-Mesa et al. 2013; Kaeberlein and Galvan 2019), extensive investigations of tetracyclines as possible new ND-modifying drugs have been initiated (Balducci and F…”
ResultAntibiotic Exposure and Risk of Parkinson's Disease in Finland: A Nationwide Case‐Control Study
Mertsalmi, T. H., Pekkonen, E., & Scheperjans, F. (2020) · Movement Disorders · doi:10.1002/mds.27924 · Cited by 88
Blood markers of oxidative stress in Alzheimer's disease
Skoumalová, A., & Hort, J. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01585.x · Cited by 87 · cited 2×
“2017; Galasko and Montine 2010; Mantzavinos and Alexiou 2017; Skoumalová and Hort 2012; Wojsiat et al.”
BackgroundGood, M. L., & Hussey, D. L. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05497.x · Cited by 87 · cited 1×
“Minocycline has also been found to have beneficial effects in inflammatory conditions and is indicated for the treatment of rheumatoid arthritis (Good and Hussey 2003).”
BackgroundInhibitory effect of minocycline on amyloid β fibril formation and human microglial activation
Familian, A., Boshuizen, R. S., Eikelenboom, P., & Veerhuis, R. (2006) · Glia · doi:10.1002/glia.20268 · Cited by 85 · cited 1×
“Considering the drug anti-Aβ activity, in vitro study of Familian and coworkers demonstrated that minocycline dose-dependently inhibit Aβ1-42 fibril formation in cell culture of adult microglia cells isolated from brains of patients with AD post-mortem (the effect was associated with inhibition of human microglial act…”
ResultTherapeutic role of rifampicin in Alzheimer's disease
Yulug, B., Hanoglu, L., Ozansoy, M., Isık, D., Kilic, U., Kilic, E., & Schabitz, W. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12637 · Cited by 81
Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models
Balducci, C., Santamaria, G., La Vitola, P., Brandi, E., Grandi, F., Viscomi, A. R., Beeg, M., Gobbi, M., Salmona, M., Ottonello, S., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.002 · Cited by 81 · cited 2×
“1 3 administration of doxycycline alone caused memory deficit comparable to that of mice treated intracerebroventricularly with synthetic Aß1–42 peptide, indicating a negative effect of the drug itself when directly injected into the brain (Balducci et al. 2018).”
BackgroundGut Microbiota: Implications in Alzheimer’s Disease
He, Y., Li, B., Sun, D., & Chen, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072042 · Cited by 81
Doxycycline Inhibits α-Synuclein-Associated Pathologies in Vitro and in Vivo
Dominguez-Meijide, A., Parrales, V., Vasili, E., González-Lizárraga, F., König, A., Lázaro, D. F., Lannuzel, A., Haik, S., Del Bel, E., Chehín, R., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105256 · Cited by 81
Costa, R., Speretta, E., Crowther, D. C., & Cardoso, I. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274548 · Cited by 80 · cited 3×
“Doxycycline-induced prevention of Aβ fibrillization and favoring of generation of non-toxic and non-amyloid structures was also confirmed in a neuroblastoma cell line studies (Costa et al. 2011).”
BackgroundInfluentialFas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain
Ethell, D. W., & Buhler, L. A. (2003) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000010420.96419.a8 · Cited by 79
Antibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million Women
Friedman, G. D., Oestreicher, N., Chan, J., Quesenberry, C. P., Udaltsova, N., & Habel, L. A. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0401 · Cited by 77
Karlsson, M., Hammers, S., Nilsson-Ehle, I., Malmborg, A. S., & Wretlind, B. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.5.1104 · Cited by 76
Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
Balducci, C., & Forloni, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00738 · Cited by 76 · cited 2×
“2013; Kaeberlein and Galvan 2019), extensive investigations of tetracyclines as possible new ND-modifying drugs have been initiated (Balducci and Forloni 2019; Molloy et al.”
BackgroundAntonenko, Y. N., Rokitskaya, T. I., Cooper, A. J. L., & Krasnikov, B. F. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9271-1 · Cited by 75
Walker, C., Preshaw, P. M., Novak, J., Hefti, A. F., Bradshaw, M., & Powala, C. (2005) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00840.x · Cited by 75 · cited 2×
“Keeping in mind the antimicrobial property-related adverse effects of tetracyclines when used as antibiotics (100–400 mg/day), and the years-long need for the therapy of widespread NDs like AD and PD, literature data indicates that the long-term administration of SDD (20–40 mg/day) used generally to treat periodontiti…”
Background
Research works printed but not linked: 8
- Beauduy CEWL (2018) Tetracyclines, macrolides, clindamycin, chloramphenicol, streptogramins, & oxazolidinones. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw Hill-Education, New York, pp 815–825
- Erekat NS (2018) Apoptosis and its role in Parkinson’s disease. In: Stoker TB, Greenland JC (eds) Parkinson’s disease: pathogenesis and clinical aspects, chapter 4. Codon Publications, Brisbane
- Forloni G, Salmona M, Marcon G et al (2012) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9(1):23–30. https://doi.org/10.2174/1871526510909010023 · DOI · Paper page
- Holmes C (2017) Inflammation in Alzheimer’s disease. In: Ames D, O’Brien JT, Burns A (eds) Dementia, 5th edn. CRC Press, Boca Raton
- Ian C, Marilyn R (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65(3):232–260. https://doi.org/10.1128/MMBR.65.2.232 · doi:10.1128/mmbr.65.2.232
- Kempuraj D, Thangavel R, Natteru PA et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1(1):1003
- Perdue BE, Standiford HC (1999) Tetracyclines. In: Yu VL, Merigan TC, Barriere SL (eds) Antimicrobial therapy and Vaccines. Williams and Wilkins, Baltimore, p 981
- Tong M, Dong M, De La Monte SM (2009) Brain Insulin-like growth factor and neurotrophin resistance in parkinson’s disease and dementia with Lewy bodies: potential role of manganese neurotoxicity. J Alzheimers Dis 16(3):585–599. https://doi.org/10.3233/JAD-2009-0995.Brain · doi:10.3233/jad-2009-0995.brain
Cited by
Qin, J., Ma, Z., Chen, X., & Shu, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1103416 · Cited by 207
“The fact that AD/PD patients (especially the changes of intestinal flora caused by antibiotics and their consequences), as well as AD and PD are universal incurable diseases that require long-term antibiotic treatment every day, constitutes a worldwide threat of bacterial resistance to these antibiotics (147).”
BackgroundVaresi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 42
Serebrovska, Z. O., Xi, L., Tumanovska, L. V., Shysh, A. M., Goncharov, S. V., Khetsuriani, M., Kozak, T. O., Pashevin, D. O., Dosenko, V., Virko, S. V., et al. (2022) · Life · doi:10.3390/life12030432 · Cited by 34
“Recent studies have underscored an anti-inflammatory and/or antioxidant therapeutic approach to reducing the rate of development of the main AD symptoms [25,26].”
Background
Metadata
- Authors
- Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M.
- Affiliations
- University Hospital Centre Zagreb (HR)
- Venue
- Journal of Neural Transmission
- Published
- 2022-01-04
- Volume
- 129
- Issue
- 5-6
- Pages
- 773-804
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W4205398889
- Cited by
- 36
- References
- 261
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 7 · 2023: 7 · 2022: 4
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Neural Transmission (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Regional Development Fund (GA KK01.1.1.01.0007)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tetracycline, drug repurposing, Alzheimer's disease, Parkinson's disease, minocycline, doxycycline, antibiotic resistance, gut microbiota, neuroprotection, chemically modified tetracyclines
- MeSH terms
- Alzheimer Disease, Animals, Anti-Bacterial Agents, Doxycycline, Humans, Minocycline, Parkinson Disease, Tetracycline, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.